The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
GlobalData on MSN
GSK’s Blenrep gains FDA approval for myeloma treatment
The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.
In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...
Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
Multiple myeloma is a chronic blood cancer affecting plasma cells, but with today’s treatments many patients can manage symptoms and live fulfilling lives. Multiple myeloma is a cancer that begins in ...
Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must ...
The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...
Bristol Myers Squibb BMY announced positive data from the late-stage study on iberdomide in patients with relapsed or refractory multiple myeloma (RRMM). The phase III EXCALIBER-RRMM (NCT04975997) is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback